Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × sacituzumab govitecan × Endocrine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 26 Genitourinary 9 Thoracic 7 Head & Neck 4 CNS 4 Tumor-Agnostic 3 Gynecologic 3 Gastrointestinal 2 Other solid neoplasm 1 Endocrine 1

Conditions

Thyroid Carcinoma, Anaplastic 1

Interventions

Everolimus 25 lutetium Lu 177 dotatate 22 Temozolomide 21 pembrolizumab 19 Cisplatin 14 lenvatinib 13 cabozantinib 13 Nivolumab 13 Magnetic Resonance Spectroscopy 13 Capecitabine 13 Sunitinib 12 Bevacizumab 12 Specimen Handling 11 Sorafenib 9 Etoposide 9 trametinib 8 pasireotide 8 dabrafenib 8 Paclitaxel 8 Ipilimumab 8 lanreotide 7 Octreotide 7 Carboplatin 7 pazopanib 6 Irinotecan 6 Injections 6 gallium Ga 68 dotatate 5 Mitotane 5 Fluorodeoxyglucose F18 5 surufatinib 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06235216 2024-11-01

SETHY

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Recruiting

EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡